Insider Selling: Natera (NASDAQ:NTRA) Insider Sells $54,881.40 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 292 shares of the company’s stock in a transaction on Tuesday, October 21st. The shares were sold at an average price of $187.95, for a total value of $54,881.40. Following the completion of the sale, the insider owned 117,267 shares of the company’s stock, valued at approximately $22,040,332.65. This trade represents a 0.25% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, October 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $159.99, for a total value of $479,970.00.
• On Tuesday, September 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $166.62, for a total value of $499,860.00.
• On Thursday, August 14th, Solomon Moshkevich sold 875 shares of Natera stock. The shares were sold at an average price of $155.46, for a total value of $136,027.50.
• On Friday, August 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $132.89, for a total value of $398,670.00.
• On Monday, July 28th, Solomon Moshkevich sold 2,206 shares of Natera stock. The shares were sold at an average price of $139.81, for a total value of $308,420.86.

Natera Stock Down 1.3%

Shares of Natera stock opened at $192.51 on Friday. The firm has a market cap of $26.42 billion, a price-to-earnings ratio of -100.79 and a beta of 1.74. The business has a fifty day simple moving average of $171.29 and a 200-day simple moving average of $160.18. Natera, Inc. has a fifty-two week low of $117.27 and a fifty-two week high of $198.99.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company had revenue of $546.60 million for the quarter, compared to analysts’ expectations of $476.84 million. During the same period in the prior year, the company earned ($0.30) earnings per share. The company’s revenue for the quarter was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. Analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

Several hedge funds have recently bought and sold shares of the business. Guided Capital Wealth Management LLC lifted its stake in Natera by 0.5% in the 2nd quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company’s stock worth $2,219,000 after acquiring an additional 66 shares in the last quarter. Main Management ETF Advisors LLC lifted its stake in Natera by 1.7% in the 2nd quarter. Main Management ETF Advisors LLC now owns 4,398 shares of the medical research company’s stock worth $743,000 after acquiring an additional 72 shares in the last quarter. Yousif Capital Management LLC lifted its stake in Natera by 4.5% in the 3rd quarter. Yousif Capital Management LLC now owns 1,682 shares of the medical research company’s stock worth $271,000 after acquiring an additional 72 shares in the last quarter. Wedmont Private Capital lifted its stake in Natera by 4.9% in the 2nd quarter. Wedmont Private Capital now owns 1,580 shares of the medical research company’s stock worth $256,000 after acquiring an additional 74 shares in the last quarter. Finally, Gries Financial LLC lifted its stake in Natera by 4.0% in the 3rd quarter. Gries Financial LLC now owns 1,904 shares of the medical research company’s stock worth $306,000 after acquiring an additional 74 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on NTRA. Piper Sandler reaffirmed an “overweight” rating and set a $220.00 target price (up from $210.00) on shares of Natera in a report on Monday, August 11th. Royal Bank Of Canada set a $268.00 target price on Natera and gave the company an “outperform” rating in a report on Tuesday, September 2nd. Morgan Stanley reaffirmed an “overweight” rating and set a $195.00 target price on shares of Natera in a report on Sunday, August 10th. Stephens reaffirmed an “overweight” rating and set a $183.00 target price on shares of Natera in a report on Friday, August 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $197.59.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.